Multiple myeloma (MM) accounts for 10% of all hematological malignancies, and is characterized by proliferation and accumulation in the bone marrow (BM) of clonal CD38+ CD138++ plasma cells and by overproduction of monoclonal proteins (M‐protein) leading to diffuse organ damage.1, 2. Here, CD38 is linked to Miyoshi myopathy.